Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Lineage Cell Therapeutics Inc (AMEX: LCTX) closed at $1.73 in the last session, down -1.14% from day before closing price of $1.75. In other words, the price has decreased by -$1.14 from its previous closing price. On the day, 0.94 million shares were traded. LCTX stock price reached its highest trading level at $1.79 during the session, while it also had its lowest trading level at $1.72.
Ratios:
We take a closer look at LCTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 4.08 and its Current Ratio is at 4.08. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.02.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Craig Hallum on August 20, 2024, initiated with a Buy rating and assigned the stock a target price of $4.
On November 02, 2022, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.B. Riley Securities initiated its Buy rating on June 14, 2022, with a $4 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Sep 24 ’25 when DON M BAILEY bought 60,000 shares for $1.60 per share.
DON M BAILEY bought 80,000 shares of LCTX for $97,472 on Sep 10 ’25. On Jan 27 ’25, another insider, BROADWOOD PARTNERS, L.P., who serves as the Director of the company, bought 7,894,737 shares for $0.76 each. As a result, the insider paid 6,000,000 and bolstered with 49,560,992 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 395056384 and an Enterprise Value of 353649376. For the stock, the TTM Price-to-Sale (P/S) ratio is 36.21 while its Price-to-Book (P/B) ratio in mrq is 8.16. Its current Enterprise Value per Revenue stands at 32.403 whereas that against EBITDA is -17.89.
Stock Price History:
The Beta on a monthly basis for LCTX is 1.85, which has changed by 1.0588236 over the last 52 weeks, in comparison to a change of 0.18258524 over the same period for the S&P500. Over the past 52 weeks, LCTX has reached a high of $1.85, while it has fallen to a 52-week low of $0.37. The 50-Day Moving Average of the stock is 15.49%, while the 200-Day Moving Average is calculated to be 93.87%.
Shares Statistics:
According to the various share statistics, LCTX traded on average about 1.61M shares per day over the past 3-months and 1658140 shares per day over the past 10 days. A total of 228.36M shares are outstanding, with a floating share count of 215.50M. Insiders hold about 5.63% of the company’s shares, while institutions hold 43.20% stake in the company. Shares short for LCTX as of 1760486400 were 31772044 with a Short Ratio of 19.73, compared to 1757894400 on 27748083. Therefore, it implies a Short% of Shares Outstanding of 31772044 and a Short% of Float of 24.83.
Earnings Estimates
Lineage Cell Therapeutics Inc (LCTX) is presently subject to a detailed evaluation by 6.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.02 and low estimates of -$0.04.
Analysts are recommending an EPS of between -$0.16 and -$0.21 for the fiscal current year, implying an average EPS of -$0.19. EPS for the following year is -$0.08, with 6.0 analysts recommending between -$0.04 and -$0.13.
Revenue Estimates
According to 7 analysts,. The current quarter’s revenue is expected to be $2.3M. It ranges from a high estimate of $3.3M to a low estimate of $1.35M. As of. The current estimate, Lineage Cell Therapeutics Inc’s year-ago sales were $3.78MFor the next quarter, 7 analysts are estimating revenue of $2.08M. There is a high estimate of $3.4M for the next quarter, whereas the lowest estimate is $383k.
A total of 7 analysts have provided revenue estimates for LCTX’s current fiscal year. The highest revenue estimate was $10.8M, while the lowest revenue estimate was $6.2M, resulting in an average revenue estimate of $8.63M. In the same quarter a year ago, actual revenue was $9.5M
